If that's all he does he will be indicted. What can

New Post Public Reply Private Reply Replies (1) Message Board
Bhawks farml1234 #44535
191
If that's all he does he will be indicted.

Quote:
What can Robert Mueller do if Trump answers under oath, “I do not remember” or “recollect” and goes off track from the questions?


Geoffrey Beebe

Answered Jan 9

For six months, I observed prosecutors in action. Here’s what I know.

If a suspect only answers “I don’t know” or “I don’t remember/recall” to every question, that’s immediately red flagged as suspicious behavior.

I’ve seen some prosecutors use that tactic alone - barring some form of mental illness, which is unlikely but possible - as grounds for obstruction of justice.

The thing is that sworn testimony only does certain things.

Bank records, investments, corporate purchases, air travel tell a much more concrete story than humans do. Did you know that the government can analyze EZ-Pass records? After all, government roads and whatnot.

You piss off the wrong prosecutor, and you better believe they can piece your life together better than you can. You think you know your life? Get an investigator to summarize your last 12 months. You can bet your butt they will.

Here’s the thing: if Trump were as smart as he thinks he is, he’d say the occasional “I don’t know/I don’t recall.” Except anyone paying attention to how he talks knows he’s not going to do that. He’s going to chump around and give verbal diarrhea. In either case, I think Mueller has a better story from the records than from any testimony he’ll be given.

He needs the lower-tiered folk to go after the big fish. That human testimony will matter.



Quote:
John Tracker, M.S. Education & Psychology, University of California, Berkeley (1997)

Answered Jan 9 · Author has 386 answers and 110.8k answer views

The “I don’t recall” defense is weak and a good prosecutor will tie a defendant down with questions that has documentation and eye witnesses so using that defense only makes it obvious the defendant is lying and could be grounds for impeachment.

Keep in mind that this investigation will also be included in a report to the DOJ and congress to consider impeachment and that is a political not criminal process and only requires the appearance of high crimes and misdemeanors.

Can Trump plead the 5th? It's complicated!

Reports are that Trump's lawyers and Mueller's team are in discussion to set up parameters under which Trump will be required to testify under oath.

The fact is Mueller holds all the cards on this decision and he has the authority to subpoena Trump to testify under oath to the grand jury.

Trump's lawyers are hoping to make a deal with Mueller to let Trump testify in some other way because they know Trump is not capable of being grilled under oath by trained professional Federal prosecutors without screwing up and perjuring himself or saying too much and incriminating himself and others.

Grand Juries are not like State Courts

Grand juries are different than state court proceedings. The defense lawyers are not even allowed to be in the room during testimony. They can be out in the hall and the defendant can go out and speak to their lawyers during the hearing for legal advice but in the hearing they are on their own.

There is no blanket protection of the 5th amendment

There is also no blanket protection of the 5th amendment. Trump can't just say he pleads the 5th to everything and refuse to testify. The law is clear that the 5th amendment only applies to answers that might incriminate the person giving testimony not other people and that incrimination must be valid that it indicates the person pleading the 5th has “real risk that [if you were to testify] your answers would tend to indicate your involvement in illegal activity[,]” Commonwealth v. Martin, 423 Mass. 496 (1996).

https://www.bostondefenselaw.com...

Consider that carefully because pleading the 5th is basically an admission you believe you may have been involved in some illegal activity.

That in itself would be grounds for congress to begin impeachment hearings as the president and all Federal officials swear an oath to uphold the constitution and laws of the land and pleading the 5th is an admission you have violated that duty.

So Trump's lawyers are in a very tough spot because they don't want Trump to testify and they don't want him to plead the 5th because either way he is likely to end up being impeached and Trump can not use the pardon power in cases of impeachment which is his only hole card to save himself and his kids from Federal charges.

They have only two real options:

1- Try to get Mueller to compromise on some form of testimony like written responses instead of an in person interview so Trump's lawyers can control his responses to keep him from perjuring himself or revealing too much and incriminating himself.

2- Convince Trump he can not testify no matter what and he should pardon himself and his kids and resign and refuse to testify. That would prevent impeachment and prevent Federal charges against Trump and his kids and then they can fight state charges for years if they are charged at the state level.

Summary

Trump's lawyers are trying to accomplish that first option now to make a deal with Mueller but if that falls through (which is likely) expect them to push Trump to strongly consider his second and only real option to pardon himself and his kids and resign.



1
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

Updated Category News Views 54

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Continue Reading
Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Updated Category News Views 70

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Continue Reading
Sempra Shines with Robust Q3 2026 Financials

Updated Category News Views 0

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Continue Reading
Coastal Financial Faces Class Action Suit Over Securities

Updated Category News Views 78

Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...

Continue Reading
Grant Davis Joins Assembly Health as CXO

Updated Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 53

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 72

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
LOA Roofing's Growth Recap Taps Southstone's Backing

Updated Category News Views 107

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

Continue Reading
SKF's Industrial Push: Energy Efficiency at COP31

Updated Category News Views 17

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Continue Reading
Eli Lilly's Retatrutide Trials Signal Innovation

Updated Category News Views 48

Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...

Continue Reading

Top 5 Most Recently Viewed Articles

SKYX Technologies Expands Market Presence with Insider Investments

Updated Category News Views 166

SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...

Continue Reading
Crinetics Pharmaceuticals Expands Workforce With Stock Options

Updated Category News Views 195

Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...

Continue Reading
Manulife Investment Management Earns Top Recognition in Sustainable Finance

Updated Category News Views 199

Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...

Continue Reading
Vaxart Reports Progress and Financial Performance for Q3 2025

Updated Category News Views 213

Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...

Continue Reading
Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study

Updated Category News Views 47

Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...

Continue Reading